RSS

Cladribine Tablets

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

The Scottish Medicines Consortium (SMC) has issued its final advice, recommending restricted use of cladribine tablets (Mavenclad, Merck) for the treatment of highly active relapsing multiple sclerosis (MS). Read more

News

Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. Read more

News

Science and technology company, Merck, has announced the availability of Mavenclad (cladribine tablets) in the UK and Ireland for the treatment of adults with highly active relapsing multiple sclerosis (MS). Read more

News

Merck has announced that the CHMP of the EMA has issued a positive opinion for approval of Cladribine tablets for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity. Read more

News